October 2018

Column

Editor's Page

Increasing Access to Innovative Therapies

10/15/2018

Winston Wong, PharmD, Editor-in-Chief

Innovations in cancer therapy hold remarkable potential to transform treatment of the disease, but it is not enough to innovate new treatments if they are not easily accessible to patients. While the issue of access...

...

10/15/2018

Journal of Clinical Pathways

Editorial

Get to Know the Community Oncology Alliance

10/15/2018

Nicolas Ferreyros, Managing Director, Community Oncology Alliance

The Community Oncology Alliance (COA) and Journal of Clinical Pathways (JCP) have joined in collaboration to keep JCP readers informed about news and research in the community oncology field, including available...

The...

10/15/2018

Journal of Clinical Pathways

Clinical Pathways GPS

Addressing High Drug Costs: Integrating Value Assessment Principles Into Clinical Pathways

10/15/2018

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor, Matthew Pakizegee, PharmD, MS

The high cost of prescription medications is a common topic of debate in oncology care and in mainstream news. Many ideas on how to reduce drug prices have been proposed and debated, but stakeholders are not close to...

The...

10/15/2018

Journal of Clinical Pathways

PATIENT PERSPECTIVE

Talking About Costs of Care—Part Two: Integrating Discussions Into the Clinical Workflow

10/15/2018

Alan Balch, PhD—Column Editor

In Part 1 of this 2-part column series on shared decision making, we discussed the need for health care teams to create a safe and inviting environment for patients to talk about financial concerns and questions...

In...

10/15/2018

Journal of Clinical Pathways

News

Conference Coverage

American Society of Clinical Oncology Quality Care Symposium

10/15/2018

JCP Editors

First launched in 2012, the American Society of Clinical Oncology (ASCO) Quality Care Symposium brings together a multidisciplinary faculty to educate attendees on the latest innovations and collaborations in quality...

First...

10/15/2018

Journal of Clinical Pathways

Feature

Research Reports

Implications of Manufacturer Contracting: A Quantitative Model to Assess Biosimilar Market Feasibility

10/15/2018

Michael Kuehn, RPh

Jay Galli

Abstract: Eight years have passed since Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) of 2010. Since then, 12 biosimilars have received approval from the Food and Drug Administration,...

...

10/15/2018

Journal of Clinical Pathways

From the Field

Evolving the Delivery of CAR T-Cell Therapies to the Outpatient Setting

10/15/2018

Sandy Smith, RN, MSN, AOCN

James Essell, MD

Abstract: The availability of adoptive cell therapies allows clinicians to genetically reprogram patients’ own immune cells to find and attack cancer cells throughout the body. Chimeric antigen receptor (CAR)...

...

10/15/2018

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

October 2018

Column

News

Feature

Current Issue

Special Reports

Subscribe

Volume 4

Specialties

Events

Year Round Education

HMP Global Products